# Anabolic-androgenic steroid use disorder - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0019 - Language: en - Last updated: not specified - Page title: Anabolic-androgenic steroid use disorder | WCP 2026 Summary > Anabolic-androgenic steroid misuse arising in the context of muscle dysmorphia leads to dependence and mood disorders, as well as fatal cardiovascular and hepa… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0019) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0019 E-PosterAddictionReview # Anabolic-androgenic steroid use disorder ANABOLIC-ANDROGENIC STEROID USE DISORDER Presenter: Estela R. Abraham Country: Argentina Anabolic-androgenic steroid misuse arising in the context of muscle dysmorphia leads to dependence and mood disorders, as well as fatal cardiovascular and hepatic outcomes in young, apparently healthy individuals. The aim of this poster is to review the relationship between muscle dysmorphia and anabolic-androgenic steroid (AAS) misuse, together with its psychiatric, cardiovascular, and hepatic consequences. The method consists of a review based on DSM-5 and selected literature, organized under the headings of epidemiology, patterns of use, clinical manifestations, and treatment. Epidemiological data indicate that 10% of male gym users may meet the criteria for muscle dysmorphia, with peak age at onset between 15 and 35 years; 90,000 cases have been reported in the United States (Olivardia, 2001) and 20,000 to 30,000 in Spain (Alonso). AAS use occurs in 1% to 6% of athletes, and two-thirds of users are noncompetitive bodybuilders or individuals without athletic goals. Cycles last 6 to 12 weeks, and total doses reach 10 to 100 times the therapeutic dose. Patterns include stacking, in which multiple androgens are used simultaneously, and pyramiding, in which doses are gradually increased and then decreased; post-cycle therapy with hCG and/or antiestrogens is also used. Psychiatric adverse effects include dependence, dysphoria and craving during withdrawal, hypomania during use and depression during withdrawal, aggression associated with personality traits (“roid rage”), alcohol dependence in 70% of users, increased opioid dependence, and increased aggressive and suicidal behavior. The section on cardiovascular and hepatic risks notes that myocardial hypertrophy, fibrosis, and repolarization abnormalities lead to fatal arrhythmias and sudden cardiac death in apparently healthy young users. It also describes accelerated atherosclerosis, thrombosis, and stroke, as well as hepatic adenoma, carcinoma, angiosarcoma, and cholestasis. Recommended treatment includes psychoeducation about withdrawal, screening for suicidal ideation, restoration of hormonal balance, and antidepressants and cognitive behavioral therapy for severe withdrawal. In conclusion, AAS misuse is particularly appealing to adolescents because it targets appearance and performance rather than euphoria; its costs include premature myocardial infarction and stroke, liver tumors, psychiatric disorders, and, when administered by injection, HIV and hepatitis. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1458) How to cite this study APA 7: Abraham, E. R. (2026, September 23-26). Anabolic-androgenic steroid use disorder [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1458 Vancouver: Abraham ER. Anabolic-androgenic steroid use disorder [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1458 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Kannabis kaynaklı psikotik bozuklukta yatışlar ve yeniden yatışlar: retrospektif bir kohort çalışması (2018 ile 2024 arası)](https://alisanburak.com/en/wcp-2026-posterler/ev0001) - [Bağımlılıklarda psikoplasti ve bütünleşik yönetim: ASAM ölçütleri kullanılarak ödül yolağının yeniden biçimlendirilmesine yönelik nörobiyolojik bir algoritma](https://alisanburak.com/en/wcp-2026-posterler/ev0003) - [Slovenya cezaevi hizmetinde depo buprenorfin uygulamasının başlatılması](https://alisanburak.com/en/wcp-2026-posterler/ev0004) - [Bağımlılıklarda metilfenidat: DEHB olan ve olmayan erişkinlerde madde kullanımı ve bağımlılık yapan davranışlara ilişkin gelişen kanıtlar](https://alisanburak.com/en/wcp-2026-posterler/ev0005) - [Malezya'da naltreksonun genişleyen klinik kullanım alanları: madde kullanımı ve madde dışı psikiyatrik bozukluklar açısından çıkarımlar](https://alisanburak.com/en/wcp-2026-posterler/ev0006) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0019 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim